Elekta's Leksell Gamma Knife Icon radiosurgery system cleared for use in China

BEIJING, February 5, 2018 – Elekta's Leksell Gamma Knife® Icon™ radiosurgery system has received clearance from the China Food and Drug Administration (CFDA), enabling health care providers in the country to offer this advanced technology to their patients. With stereotactic imaging, automatic delivery correction and dose evaluation for ultra-precise dose delivery, as well as the availability of frameless treatments, Icon is capable of treating virtually any target in the brain, regardless of type, location or volume.

Gamma Knife is the leading stereotactic radiosurgery (SRS) platform, offering unparalleled accuracy in both the localization and radiation dose delivered to targeted brain tissue. In China, more than 100,000 people are diagnosed each year with brain cancer[1], just one of the indications that can benefit from treatment with the high precision of Leksell Gamma Knife Icon. Other traditional indications for Gamma Knife radiosurgery include benign lesions, such as meningiomas; arteriovenous malformations and other vascular disorders; and functional disorders, such as trigeminal neuralgia.

Gamma Knife Icon represents the sixth generation of the company’s Leksell Gamma Knife system, a technology that has been in use worldwide and continually evolving since the 1960s. Gamma Knife radiosurgery is a gentler alternative to traditional brain surgery and whole brain radiation therapy for illnesses such as metastatic disease, which is cancer that has travelled to the brain from elsewhere in the body. With pinpoint accuracy, the system delivers up to thousands of low-intensity radiation beams to one or more targets in single or fractionated sessions.

Anming Gong, Elekta’s Executive Vice President Region China, says: “Icon is the result of almost 50 years of innovation and decades of collaboration with surgeons and radiation oncologists around the globe. We are very pleased that the latest development of the world’s only SRS system designed specifically to target brain tissue will now be available to patients in China.”

To date, more than 1.1 million people around the world have received Gamma Knife radiosurgery and the technology is consistently commended for its excellent clinical performance. “The new Gamma Knife Icon system has innovative features that allow for greater potential to protect the patient’s quality of life, both during treatment and after recovery,” Gong adds. “Unlike surgery, there is no hospitalization, convalescence or rehabilitation required and patients typically return to their regular lives within a few days after treatment. With Leksell Gamma Knife, more patients can receive the best brain care possible.”

For more information on Icon, visit www.elekta.com/icon.

# # #

[1] Cancer statistics in China, 2015, DOI: 10.3322/caac.21338

About Elekta

Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm www.elekta.com



PDF Version

For further information, please contact

Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242,
E-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time

Raven Canzeri, Global Public Relations Manager, Elekta
Tel: +1 770-670-2524,
E-mail: raven.canzeri@elekta.com
Time zone: ET: Eastern Time